CoChat

Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Programmed cell death ligand 1 (PD-L1) is an important immune-inhibitory protein expressed on cancer cells to mediate cancer escape through interaction with PD-1 expressed on activated T lymphocytes (T cells). Previously, we reported that colon and breast cancer stem cells (CSCs) expressed much higher levels of PD-L1 than their parental cells, suggesting they will be more resistant to immune attack. METHODS: We investigated the underlining mechanism of PD-L1 increase in colon CSCs, with a special focus on the effect of insulin and epithelial growth factor (EGF), the two fundamental components to sustain the metabolism and stemness in the culture of CSCs. RESULTS: We found that insulin increased the total and surface PD-L1 levels through PI3K/Akt/mTOR pathway as the increase could be inhibited by the dual inhibitor of the pathway, BEZ235. EGF didn't affect the total PD-L1 levels of CSCs but increased the cell surface protein levels by flow cytometry analysis, indicating EGF promotes the transport of PD-L1 to the cell surface. Blocking cell surface PD-L1 with a specific antibody resulted in a significant reduction of tumour sphere formation but didn't interfere with the sphere growth, suggesting that cell surface PD-L1 may act as an adhering molecule for CSCs. CONCLUSIONS: Apart from the essential roles in metabolism and stemness, insulin and EGF involve in up-regulation of PD-L1 expression in colon CSCs, therefore the inhibition of insulin and EGF/EGFR pathways can be considered for cancer immunotherapy or combined with PD-1/PD-L1 antibody-based cancer immunotherapy to eliminate CSCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-019-5364-3

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow cytometry analysis of CSC markers of HT-29 spherical cells. After sphere culture for enrichment of cancer stem cells, the HT-29 spherical (SP) cells were labelled and analysed for the expression of CD24, CD44, and CD133 using flow cytometer. The expression of CD24, CD44, and CD133 of HT-29 spherical cells were significantly increased (a, HT-29 vs HT-29SP). The fold changes of mean fluorescent intensity (MFI) from 3 repeated FACS analysis show the same trend (b)
Fig. 1 Flow cytometry analysis of CSC markers of HT-29 spherical cells. After sphere culture for enrichment of cancer stem cells, the HT-29 spherical (SP) cells were labelled and analysed for the expression of CD24, CD44, and CD133 using flow cytometer. The expression of CD24, CD44, and CD133 of HT-29 spherical cells were significantly increased (a, HT-29 vs HT-29SP). The fold changes of mean fluorescent intensity (MFI) from 3 repeated FACS analysis show the same trend (b)CC BY · PubMed Central
Fig. 2 PD-L1 expression increased in CSCs from HT-29. a, Western Blotting analysis of PD-L1 protein levels in HT-29 cancer cells and tumour spherical cells from HT-29 (HT-29 SP). b, flow cytometry analysis of PD-L1 positive cells. Comparing with the isotype controls (ISO) HT-29 spherical cells (HT-29 SP) had more (about 10% increase of PD-L1 positive cells. c, a histogram analysis of PD-L1 expression in HT-29 cells and HT-29SP. d. the fold changes of MFI from c
Fig. 2 PD-L1 expression increased in CSCs from HT-29. a, Western Blotting analysis of PD-L1 protein levels in HT-29 cancer cells and tumour spherical cells from HT-29 (HT-29 SP). b, flow cytometry analysis of PD-L1 positive cells. Comparing with the isotype controls (ISO) HT-29 spherical cells (HT-29 SP) had more (about 10% increase of PD-L1 positive cells. c, a histogram analysis of PD-L1 expression in HT-29 cells and HT-29SP. d. the fold changes of MFI from cCC BY · PubMed Central
Fig. 3 Insulin but not EGF increases PD-L1 expression in non-CSCs. Insulin treatment can increase PD-L1 expression in non-cancer stem cells of HT-29 but the treatment needs to be 6 days to be able to display by Western blotting assay (a). In contrast, EGF treated HT-29 didn’t show PD-L1 protein band even after 6 days and only have the band after co-treatment with insulin. b shows a dose-dependent increase of PD-L1 protein from 1μg/ml to 20 μg/ml insulin. Like b, c shows the dose-dependent increase of PD-L1 by flow cytometry analysis
Fig. 3 Insulin but not EGF increases PD-L1 expression in non-CSCs. Insulin treatment can increase PD-L1 expression in non-cancer stem cells of HT-29 but the treatment needs to be 6 days to be able to display by Western blotting assay (a). In contrast, EGF treated HT-29 didn’t show PD-L1 protein band even after 6 days and only have the band after co-treatment with insulin. b shows a dose-dependent increase of PD-L1 protein from 1μg/ml to 20 μg/ml insulin. Like b, c shows the dose-dependent increase of PD-L1 by flow cytometry analysisCC BY · PubMed Central
Fig. 4 EGF helps in PD-L1 transport to cell surface. a, shows that after EGF treatment the PD-L1 levels on cell surface increases analysed by flow cytometry analysis, compared to isotype control. Together with insulin EGF treatment can further increase the level. b, shows the MFI of repeated flow cytometry analysis. EGF treatment alone the MFI increased 44.7%, compared to isotype control. When co-treated with insulin, the MFI of EGF treatment further increased 20.4%, suggesting that EGF treatment is associated with membrane PD-L1 levels. c, shows the WB assay for PD-L1 in the cell membrane isolated from HT-29 cells treated with insulin or EGF+ insulin
Fig. 4 EGF helps in PD-L1 transport to cell surface. a, shows that after EGF treatment the PD-L1 levels on cell surface increases analysed by flow cytometry analysis, compared to isotype control. Together with insulin EGF treatment can further increase the level. b, shows the MFI of repeated flow cytometry analysis. EGF treatment alone the MFI increased 44.7%, compared to isotype control. When co-treated with insulin, the MFI of EGF treatment further increased 20.4%, suggesting that EGF treatment is associated with membrane PD-L1 levels. c, shows the WB assay for PD-L1 in the cell membrane isolated from HT-29 cells treated with insulin or EGF+ insulinCC BY · PubMed Central
Fig. 5 PI3K/Akt dual inhibitor BEZ235 dose-dependent inhibition of insulin-induced PD-L1 expression. a, shows flow cytometry results of BEZ235 inhibitory effect on PD-L1 expression. b shows the inhibitory effect on protein levels of BEZ235 by Western blotting assay
Fig. 5 PI3K/Akt dual inhibitor BEZ235 dose-dependent inhibition of insulin-induced PD-L1 expression. a, shows flow cytometry results of BEZ235 inhibitory effect on PD-L1 expression. b shows the inhibitory effect on protein levels of BEZ235 by Western blotting assayCC BY · PubMed Central
Fig. 6 Blocking surface PD-L1 inhibits tumour sphere formation. Antibody blocking PD-L1 or isotype antibody (Isotype Ab) was added into the sphere culture medium and the blockage of PD-L1 inhibited the sphere number (P < 0.05, a), compared to both untreated and isotype controls. However, the antibody blocking didn’t affect the sphere size (cells/sphere, b)
Fig. 6 Blocking surface PD-L1 inhibits tumour sphere formation. Antibody blocking PD-L1 or isotype antibody (Isotype Ab) was added into the sphere culture medium and the blockage of PD-L1 inhibited the sphere number (P < 0.05, a), compared to both untreated and isotype controls. However, the antibody blocking didn’t affect the sphere size (cells/sphere, b)CC BY · PubMed Central
Fig. 7 Schematic diagram illustrating insulin-induced PD-L1 up-regulation and EGF help in PD-L1 transport in colon CSCs. Insulin binds to its receptor IR and activates the IRS which phosphorylate the PI3K. Activated PI3K can activate AKT through PIP3 and phosphorylate AKT. A downstream target of AKT is mTOR, that can lead to activation and translocation of possible S6K into the nucleus [46, 47] and subsequent start of the PD-L1 transcription and PD-L1 protein production. Cytoplasmic PD-L1 proteins will be transferred to cell membrane through EGF/EGFR-mediated transport or stabilization on the cell membrane. Because BEZ235 can inhibit both AKT and mTOR thus reduce PD-L1 production via this pathway
Fig. 7 Schematic diagram illustrating insulin-induced PD-L1 up-regulation and EGF help in PD-L1 transport in colon CSCs. Insulin binds to its receptor IR and activates the IRS which phosphorylate the PI3K. Activated PI3K can activate AKT through PIP3 and phosphorylate AKT. A downstream target of AKT is mTOR, that can lead to activation and translocation of possible S6K into the nucleus [46, 47] and subsequent start of the PD-L1 transcription and PD-L1 protein production. Cytoplasmic PD-L1 proteins will be transferred to cell membrane through EGF/EGFR-mediated transport or stabilization on the cell membrane. Because BEZ235 can inhibit both AKT and mTOR thus reduce PD-L1 production via this pathwayCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 53

Metadata

Authors
Chen, M., Sharma, A., Lin, Y., Wu, Y., He, Q., Gu, Y., Xu, Z. P., Monteiro, M., & Gu, W.
Affiliations
The University of Queensland (AU)
Corresponding author
Gu, Wenyi
Venue
BMC Cancer
Published
2019-02-15
Volume
19
Issue
1
Pages
153-153
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2919282928
Cited by
53
References
48
Citations by year
2026: 4 · 2025: 2 · 2024: 13 · 2023: 7 · 2022: 9 · 2021: 7 · 2020: 6 · 2019: 5
FWCI
2.82
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
University of Queensland
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
PD-L1, colon cancer stem cells, insulin, epithelial growth factor, EGFR signaling, PI3K/AKT/mTOR pathway, BEZ235, tumor immunosuppression, cancer immunotherapy, PD-1/PD-L1 blockade
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Antibodies, Monoclonal, Antineoplastic Agents, Cell Membrane, Colonic Neoplasms, Cytoplasm, Epidermal Growth Factor, Humans, Imidazoles, Immunotherapy, Insulin, Quinolines, Neoplastic Stem Cells, Up-Regulation, HT29 Cells, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, B7-H1 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells. https://app.cochat.ai/papers/10.1186/s12885-019-5364-3
The paper
Chen, M., Sharma, A., Lin, Y., Wu, Y., He, Q., Gu, Y., Xu, Z. P., Monteiro, M., & Gu, W. (2019). Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells. BMC Cancer. https://doi.org/10.1186/s12885-019-5364-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.